Spark carefully records a safe step forward for closely-watched hemophilia gene therapy – Endpoints News
Endpoints News |
Spark carefully records a safe step forward for closely-watched hemophilia gene therapy
Endpoints News Four months after rattling investors with evidence of an immune reaction to its gene therapy, Spark Therapeutics $ONCE is updating its data on the Phase I/II study of its hemophilia B treatment, offering fresh evidence that researchers were able to … Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and … |
